A total of 62 patients were enrolled in the Phase II trial at six sites throughout the US. Osiris is investigating Prochymal in patients with chronic obstructive pulmonary disease (COPD), reported to be the fourth leading cause of death in the US.
Michelle Williams, vice president of development at Osiris, said: “We are excited to learn more about the therapeutic utility of these cells in the lungs, not only for the treatment of COPD, but for other pulmonary conditions as well. This study will provide for us the necessary base for further rapid development of this remarkable stem cell technology in what could ultimately prove to be a broad spectrum of lung diseases.”